

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ETHK^{.com} Labs

华检医疗 (1931.HK)

IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

SUPPLEMENTAL ANNOUNCEMENT

- (1) UPDATE ON STABLECOIN LICENSE APPLICATION PROGRESS;**
- (2) MAJOR ACQUISITION IN RELATION TO
THE POTENTIAL CRYPTOCURRENCY ACQUISITIONS;**
- (3) LASPE OF DISCLOSEABLE TRANSACTION IN RELATION TO
THE ACQUISITION OF THE SHARES IN
GOFINTECH QUANTUM INNOVATION LIMITED; AND**
- (4) FURTHER ELABORATION ON THE STRATEGIC DEVELOPMENT
DIRECTION OF THE GROUP**

Reference made to (i) the announcement of IVD Medical Holding Limited (the “**Company**”) on 17 July 2025, and the voluntary announcement on the strategic progress issued on 20 July 2025; (ii) the voluntary announcement on 8 August 2025 (the “**Announcement**”), in relation to, among other things, the launch of the Group’s “ivd.xyz Exchange” – the world’s first real-world asset (“**RWA**”) exchange ecosystem focusing on medical innovative drug NewCo high-tech assets and the ‘IVDD’ stablecoin program, committed to revolutionizing the capital efficiency and globalization process of the medical innovative drugs industry through the “NewCo + RWA” Web3 exchange ecosystem operation model, addressing the long-standing pain points of low financing efficiency, poor asset liquidity, and high globalization barriers in the industry; (iii) the announcement regarding possible major transaction dated 15 August 2025, in relation to, among other things, the application of the specific mandate regarding the potential acquisitions of cryptocurrencies up to HK\$3 billion in open market transactions; (iv) the announcement of the Company dated 1 September 2025 in relation to, among other things, the acquisition of 1,848,496,429 shares of GoFintech Quantum Innovation Limited (the “**Target Company**”) (representing approximately 20.31% of the entire issued share capital of the Target Company) (the “**Acquisition**”) involving the issuance of consideration shares under the general mandate; and (v) the announcement dated 22 October 2025 regarding the proposed change of the Company’s English name and corporate logo (the “**Name Change Announcement**”). Unless otherwise defined, capitalised terms and expressions used in this announcement shall have the same meanings as those defined in the Announcement. The Company would like to provide supplemental information in respect of the new business model described in such announcements and current business development.

BUSINESS MODEL ARCHITECTURE AND OPERATIONAL IMPLEMENTATION

The Company's new business initiative aforementioned comprises three core components, which together form a closed-loop ecosystem for the tokenization and exchange of RWAs derived from the intellectual property for medical innovative drugs and/or high-tech assets possessing potential value:

The ivd.xyz Exchange Platform serves as the world's first dedicated RWA exchange for medical innovative drugs intellectual property, enabling the issuance, trading, and liquidity construction of tokenized assets. All exchange revenues—including transaction fees and RWA appreciation—are automatically converted to Ether ("ETH") via smart contracts or US Dollars, thereby strengthening the Company's treasury reserves and creating a self-reinforcing financial mechanism.

The RWA Tokenization process involves acquiring high-potential drug pipelines and transforming their intellectual property ("IP") into on-chain RWAs through the ivd.xyz Exchange. This enables fractional ownership and secondary market circulation, attracting global capital and enhancing liquidity. A Dynamic Recycling Mechanism ensures that profits generated from RWAs are systematically converted into ETH or US Dollars, forming a sustainable "IP → RWA → ETH/US Dollars" value chain that continuously fuels further investment in innovative medical assets.

Also, the IVDD Stablecoin system provides a compliant stablecoin pegged to assets within the aforementioned RWA exchange ecosystem. It serves as the primary medium for transaction settlements within the exchange, providing the ecosystem with efficient, low-friction cross-border payment and clearing capabilities, and facilitates on-chain revenue distribution. IVDD is designed to comply with Hong Kong's Stablecoin Ordinance and relevant U.S. regulations, ensuring full reserve backing and robust anti-money laundering protocols. **The Company disclosed in its earlier announcement its intention to issue IVDD, a proprietary stablecoin designed to complement the RWA exchange ecosystem for medical innovative drugs. This proposal is preliminary and does not currently meet the requirements of the stablecoin ordinances in Hong Kong and the US. If approval for the peg to the medical RWA assets is not granted, the Company will apply for a Hong Kong Stablecoin License or a US Stablecoin License, backed by US dollars. The Board is considering raising funds by issuing preference shares or convertible bonds, or by using internal resources, to ensure sufficient Hong Kong Dollars or US Dollars are available as reserves for the application of the Hong Kong Stablecoin License or US Stablecoin License.** It is expected that the Group will begin applying for the US Stablecoin License first, given the more advanced regulatory developments in the US Stablecoin market, and will increase its US Dollars reserve by fund raising activities to meet its requirements. For further details regarding the Group's stablecoin initiatives, please refer to the announcement issued by the Company on 13 October 2025.

These elements are deeply interconnected and form a closed-loop ecosystem that transforms IP for medical innovative drugs into tradable digital assets, enables liquid secondary markets, converts economic gains into ETH or US Dollars, and reinvests proceeds into new intellectual property acquisitions. This end-to-end integration is designed to enhance capital efficiency, accelerate drug development cycles, and bridge the gap between medical innovation and crypto-financial markets.

The Company will operate and monitor the new business through a structured governance model led by the Board of Directors, supported by a dedicated Risk Management Committee overseeing ETH treasury strategies and hedging parameters.

The Company will ensure compliance through acquisition or collaboration with dual licensing firms in Hong Kong (Type 1 for securities and Type 7 for automated trading services), third-party audits for RWA valuation and smart contract security, and strict adherence to cross-jurisdictional regulations—including Hong Kong’s Stablecoin Ordinance, the U.S. GENIUS Act, and other international frameworks.

The Board believes that this pioneering fusion of tokenization of medical innovative drugs/high-tech assets and blockchain-based finance will not only set a new benchmark for investment in medical innovation but also generate sustainable value for the Company and its shareholders by unlocking global capital, mitigating traditional market inefficiencies, and positioning core business segment in in vitro diagnostics (“IVD”) at the forefront of the digital transformation of life sciences.

FURTHER ELABORATION ON THE GROUP’S STRATEGIC DEVELOPMENT DIRECTION

Following the strategic closed loop of financing-mergers and acquisitions-integration to sustained profitability outlined in the Name Change Announcement, the Board hereby elaborates further on the Group’s future strategic development direction. This actively responds to the national strategies proposed in the “Proposal of the Central Committee of the Communist Party of China on Formulating the 15th Five-Year Plan for National Economic and Social Development”, including “cultivating and expanding emerging industries and future industries”, “comprehensively implementing the “AI+” initiative to drive paradigm shifts in scientific research through artificial intelligence”, and emphasising the leading role of technological innovation.

The Group will anchor its strategy within the national framework of promoting self-reliance and strength in science and technology. By deeply integrating artificial intelligence technology with the life sciences industry, it will systematically advance the following strategic upgrades:

1. Strengthening the integrated application of “AI Algorithms + Life Sciences”: The Group will actively deploy resources towards artificial intelligence technologies, particularly the deep application of Generative AI within the life sciences sector. Through independent R&D and collaborative introductions, it will establish proprietary AI algorithm platforms aimed at enhancing the efficiency of identifying, the accuracy of valuing, and the effectiveness of integrating high-tech intellectual property (“K”) assets within the global life sciences domain.

2. Empowering intelligent synergy across three strategic curves: This AI algorithm capability will be deeply integrated with the Group's existing three strategic curves (K1: IVD distribution network, K2: IVD ecosystem, K3: RWA securitisation platform). Algorithm-driven optimisation will enhance supply chain and market insights for Curve K1; accelerate intellectual property screening, evaluation, and collaborative innovation for Curve K2; enhance the valuation model accuracy for underlying assets in the third curve (K3), alongside improving efficiency and transparency throughout the securitisation process.
3. Precision-focused algorithm-driven consolidation of controlling stakes in life sciences listed companies: Moving forward, the Group will increasingly prioritise advanced technological methods, including AI algorithms, when executing global mergers and acquisitions. This will enable systematic analysis, precise identification, and efficient consolidation of controlling stakes or core intellectual property within life sciences listed companies meeting the criteria of "high-tech, global reach, and substantial assets". This initiative aims to establish a technology-driven, synergistic cluster of globally listed high-tech life science enterprises, serving the nation's macro-level deployment of strategic emerging industries and future industries.

The Board believes this strategic upgrade not only actively responds to the national "AI Plus" initiative and the strategy for technological self-reliance and self-strengthening, but will also significantly enhance the Group's core competitiveness within the global life sciences sector. Through a closed-loop approach of "investment, merger, management and exit empowered by AI algorithms", it will more efficiently realise the value transformation "from knowledge to capital", creating long-term and sustainable returns for shareholders.

MANAGEMENT EXPERTISE AND GOVERNANCE STRUCTURE

The Directors and senior management team possess extensive experience and specialized knowledge in the medical technology sector, particularly in the field of IVD. Their expertise in navigating the complexities of the medical industry, including clinical trials and regulatory approvals, positions the new business to capitalize on emerging opportunities. To further strengthen the execution capabilities of the new business initiative, the Company will establish a dedicated New Business Task Force. Concurrently, we are actively seeking qualified Responsible Officers possessing Hong Kong Securities and Futures Commission (SFC) Type 7 (Automated Trading Services) licenses or candidates with proven track records in both traditional finance and emerging digital asset sectors, particularly those with experience in regulated financial services environments and an understanding of cross-jurisdictional compliance requirements to ensure regulatory compliance and proper governance of our trading platform operations.

POTENTIAL ACQUISITION MANDATE

Reference is made to the voluntary announcement of the Company dated 15 August 2025 in relation to, among others, the application of the specific mandate regarding the potential acquisitions of cryptocurrencies up to HK\$3 billion in open market transactions (“**the Application**”). In view of additional time is required to approve the specific mandate for the potential cryptocurrency acquisitions in the extraordinary meeting, the Board decided not to proceed the Application as of the date of this announcement. Instead, if the Company continues the purchase of the ETH in the future, it will make a further announcement in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited especially Chapter 14 as and when appropriate.

LASPE OF DISCLOSEABLE TRANSACTION IN RELATION TO THE ACQUISITION OF THE SHARES IN GOFINTECH QUANTUM INNOVATION LIMITED

Pursuant to the conditional sale and purchase agreement (the “**Sale and Purchase Agreement**”) entered into by Final Touch Ltd. (the “**Purchaser**”), a wholly-owned subsidiary of the Company, Dr. Liu Zhiwei, AI International Capital Management Ltd., and Caitex Technology Holdings Limited (collectively the “**Vendors**”) dated 1 September 2025, pursuant to which, the Purchaser has conditionally agreed to acquire and the Vendors have conditionally agreed to sell 1,848,496,429 shares of the Target Company (representing approximately 20.31% of the entire issued share capital of the Target Company), if any of the conditions precedent to the completion of Acquisition (the “**Conditions Precedent**”) are not fulfilled (or waived) on or before the Long Stop Date (i.e. 31 October 2025), the Sale and Purchase Agreement shall be terminated, and all rights, obligations and liabilities of the parties thereto shall cease and determine and neither party shall have any claim against the other, save for any antecedent breaches of the Sale and Purchase Agreement.

As certain Conditions Precedent under the Sale and Purchase Agreement has not been fulfilled or waived by the Long Stop Date, the Sale and Purchase Agreement has lapsed on 31 October 2025 pursuant to the terms thereof and shall cease to be of any effect and neither party shall have any obligations and liabilities thereunder.

The execution of the tokenization of medical innovative drug assets and the application for a stablecoin backed by RWA assets for innovative medical drugs are subject to Hong Kong’s Stablecoin Ordinance, the U.S. GENIUS Act, and the relevant regulations. There is therefore no assurance that the tokenization of medical innovative drug assets and the proposal for the stablecoin backed by RWA assets for innovative medical drugs can proceed successfully in Hong Kong or the USA. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
IVD Medical Holding Limited
Lin Xianya
Executive Director

Hong Kong, 31 October 2025

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken, Mr. Law Kim Fai and Ms. Tai Yang, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and four independent non-executive directors, namely, Dr. Leung Ka Sing, Dr. Wong Sze Lok, Mr. Xu Da and Mr. Zhang Jianlei.

This announcement contains forward-looking statements that reflect the Company's beliefs, plans or expectations about the future or future events. These statements are based on a number of assumptions, current estimates and projections, and are subject to risks, uncertainties and factors which may be beyond control. Actual outcomes may differ. These statements are not, and shall not be, relied upon as any assurance or representation as to the future or as a representation or warranty otherwise. Neither the Company nor its directors, officers, employees, agents, affiliates, advisers or representatives assume any responsibility to update these statements or to adapt them to future events or developments or to provide supplemental information in relation thereto or to correct any inaccuracies.

If there is any inconsistency between the Chinese and English versions of this announcement, the Chinese version shall prevail.